The FDA insisted on a combo trial. Why? Possibly because Cytodyn could do a smaller phase 3 trial in combo therapy using the monotherapy data as support which would mean quicker approval. The FDA also wanted a combo trial so there was a backup drug because they didn't trust in the efficacy of leronlimab based on the results from maraviroc.

Maybe once the HIV trial data is published in a peer reviewed journal the FDA will get a clue.